Cannabis Seniors Research

A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer's Disease.

Rosenberg, Paul B · 2026

In a 3-week RCT of 75 Alzheimer's patients, dronabinol decreased agitation significantly more than placebo on the Pittsburgh Agitation Scale (effect size 0.53, p=0.015).

Lifetime Cannabis Use Is Associated with Brain Volume and Cognitive Function in Middle-Aged and Older Adults.

Guha, Anika · 2025

Using UK Biobank data from participants aged 40-70 (mean age 54.5), lifetime cannabis use was positively associated with regional brain volume in CB1-rich areas including the caudate, putamen, hippocampus, and amygdala.

Cannabis Legalization and Opioid Use Disorder in Veterans Health Administration Patients.

Mannes, Zachary L · 2025

OUD prevalence increased by 0.06 percentage points after medical cannabis law enactment and 0.07 points after recreational law enactment.

Risk of Dementia in Individuals With Emergency Department Visits or Hospitalizations Due to Cannabis.

Myran, Daniel T · 2025

Individuals aged 45+ with acute care due to cannabis use had a 5.0% rate of dementia diagnosis within 5 years, compared to 3.6% for all-cause acute care and 1.3% in the general population.

Cannabis Use Among Older Adults.

Pravosud, Vira · 2025

Of 4,503 veterans aged 65-84, 58.2% had ever used cannabis.

Adverse events caused by cannabinoids in middle aged and older adults for all indications: a meta-analysis of incidence rate difference.

Velayudhan, Latha · 2024

THC alone and THC:CBD combinations significantly increased all-cause and treatment-related adverse events compared to controls.

Associations of Healthcare Service Utilization With Cannabis Use Status, Use Reasons, and Use Characteristics Among Those Age 50 and Older.

Choi, Namkee G · 2022

Past-year cannabis users had higher rates of any ED visit (30.0%) and hospitalization (14.7%) than never users.

Association of a Positive Drug Screening for Cannabis With Mortality and Hospital Visits Among Veterans Affairs Enrollees Prescribed Opioids.

Keyhani, Salomeh · 2022

Cannabis use was not associated with all-cause mortality at 90 or 180 days in the overall population or among those on long-term opioid therapy.

Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019.

Han, Benjamin H · 2021

Perceived risk of regular cannabis use decreased 18.8% overall among older adults.

Prevalence of cannabis use, disorder, and medical card possession in U.S. military veterans: Results from the 2019-2020 National Health and Resilience in Veterans Study.

Hill, Melanie L · 2021

Cannabis use prevalence among veterans was estimated at 11.9%, up from 9% in 2014.

Cannabis or drug screening and discussions with clinicians among older adults who use cannabis in the US, 2021-2023.

Mauro, Pia M · 2026

36.8% of US adults 65+ reported drug screening at healthcare visits.

Age differences in endocannabinoid tone are ameliorated after recent cannabis use.

Morris, Alan W J · 2026

Older adults (55-71) had lower baseline AEA and DEA vs.

Treatment with a botanical mixture of cannabidiol:Δ9-tetrahydrocannabinol enhances microglial phagocytosis and shapes amyloid plaques in a mouse model of Alzheimer's disease.

Ruiz de Martín Esteban, Samuel · 2026

Chronic treatment (28 days) with CBD:THC (99:1) at 50 mg/kg twice daily in 5xFAD Alzheimer's mice enhanced microglial phagocytic activity and reduced amyloid peptide accumulation in neuritic plaques.

Recent Trends in Cannabis Use in Adults Ages 60 Years and Older.

Thayer, Rachel E · 2026

Most older adults who use cannabis report doing so for medical purposes, primarily targeting pain, insomnia, anxiety, and depression.

Association between cannabis consumption and serum Klotho levels in middle-aged U.S. adults: NHANES cross-sectional analysis.

Wang, Li · 2026

Frequent cannabis users had significantly lower Klotho levels than never users (adjusted estimate = -57.94, p = 0.027), with a significant dose-dependent trend (p = 0.022).

Current marijuana use is cross-sectionally associated with accelerated biological aging among U.S. adults: exploring mediating effect of blood cadmium.

Wei, Kai · 2026

Current marijuana users showed significantly accelerated aging versus never users on both PhenoAge (beta = 0.72, p < 0.001) and KD-BioAge (beta = 0.36, p = 0.002).

Concomitant use of medical cannabis and drugs associated with risks of interaction in older patients: a longitudinal cohort study.

Bérété, Zoumana Cheick · 2025

The drug interaction studies in the laboratory (RTHC-00091, RTHC-00104) have shown that cannabinoids inhibit liver enzymes that metabolize many medications.

A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease.

Cury, Rafael de Morais · 2025

Patients receiving low-dose THC-CBD extract (0.350 mg THC + 0.245 mg CBD daily) had significantly higher Mini-Mental State Exam scores at week 26 compared to placebo..

Opioid Initiation in Older Patients with Chronic Pain Who Received Authorized Cannabis Prescription.

Fontaine, Emilie · 2025

Among 3,427 opioid-naive patients 66+ with cannabis prescriptions, 1.84/100 person-years initiated 90+ day opioids vs 1.19/100 in 12,006 controls.

Neural Signatures of Cannabis Use: Reversing Cognitive Aging via Whole-Brain Functional Network Connectivity.

Fu, Zening · 2025

Cannabis use and healthy aging were associated with overlapping brain network configurations, particularly between subcortical-sensorimotor and subcortical-cerebellar regions, but with significantly reversed effects.

Association of Smoking Cannabis With Cardiovascular Events Among Veterans With Coronary Artery Disease.

Keyhani, Salomeh · 2025

This is one of the largest and most rigorous studies to examine whether cannabis smoking affects cardiovascular outcomes in people who already have heart disease.

Age Differences in Cannabis Consumption Patterns and in Associations Between Delta-9-Tetrahydrocannabinol Intake and Cannabis Use Disorders Among Adults with Daily Use.

Livne, Ofir · 2025

Over 70% of daily users across all ages used cannabis for both medical and recreational reasons.

Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions.

Mello-Hortega, João V · 2025

CBD has demonstrated effects on amyloid plaques, tau protein, neuroinflammation, oxidative stress, and cholinergic pathways in preclinical Alzheimer's models.

Cannabidiol and cognitive functions/inflammatory markers in Parkinson's disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial).

Mitarnun, Witoon · 2025

Among 51 Parkinson's patients completing the trial, low-dose CBD (26 mg/day) was safe with no serious side effects.

Age-Related Effects of Cannabis and Cannabinoids on Brain and Behavior.

Murray, Conor H · 2025

Recent epidemiological data suggest a potential reversal in escalating cannabis use rates among pregnant women and adolescents, but use among older adults continues to climb with low risk perception.

Marijuana use among community-dwelling older adults: A population-based study.

De Genna, Natacha M · 2024

Cannabis research in older adults has mostly relied on convenience samples — people recruited from dispensaries or cannabis clinics who are already enthusiastic users.

Effects of medical cannabis use on physical and psychiatric symptoms across the day among older adults.

Dvorak, Robert D · 2024

Across 5,156 momentary assessments over 1,106 use days, all measured symptoms declined after cannabis use.

Primary Care Providers' Communication About Medical Cannabis With Older Adults: A Cross-Sectional Survey.

Elbready, Abdallah W · 2024

Primary care providers were more likely to inquire about alcohol and tobacco use than cannabis with older adult patients.

Associations of cannabis use with motor vehicle crashes and traffic stops among older drivers: AAA LongROAD study.

Davis, Shelby · 2023

Of 2,095 active drivers aged 65-79, 186 (8.9%) used cannabis in the past year.

Cannabis use for Sleep Disturbance Among Older Patients in a Geriatrics Clinic.

Kaufmann, Christopher N · 2023

Cannabis use among older adults is growing fast, and sleep is one of the top reasons cited.

Chronic health conditions, acute health events, and healthcare utilization among adults over age 50 in Hawai'i who use cannabis: A matched cohort study.

Phillips, Kristina T · 2022

Cannabis-diagnosed patients had significantly greater risk of coronary heart disease, chronic non-cancer pain, stroke, myocardial infarction, cyclic vomiting, and injuries compared to age- and sex-matched controls.

Dos(e)Age: Role of Dose and Age in the Long-Term Effect of Cannabinoids on Cognition.

Zamberletti, Erica · 2022

Prenatal and adolescent cannabinoid exposure consistently led to long-term cognitive deficits in animal models, while exposure in aged animals showed potential beneficial effects on cognition.

Cannabinoids for the treatment of dementia.

Bosnjak Kuharic, Dina · 2021

Across four RCTs testing natural and synthetic THC, there was very low certainty evidence of minimal effect on cognition (1.1-point sMMSE difference) and low certainty evidence of minimal effect on behavioral symptoms (-1.97 NPI difference).

Sex differences in cannabis forms and exposure reasons in cannabis-related poison control center cases aged 50.

Choi, Namkee G · 2021

Women over 50 had 1.93 times greater odds of calling about therapeutic errors/adverse reactions compared to intentional misuse.

Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009-2019.

Choi, Namkee G · 2021

Cases increased 18-fold (61 to 1,074) over the decade.

Cannabis: An Emerging Treatment for Common Symptoms in Older Adults.

Yang, Kevin H · 2021

15% of geriatric clinic patients used cannabis.

Cannabinoids in the Older Person: A Literature Review.

Beedham, William · 2020

From 35 relevant studies, cannabinoids demonstrate some efficacy for pain and chemotherapy-related nausea.

Persistence of use of prescribed cannabinoid medicines in Manitoba, Canada: a population-based cohort study.

Alkabbani, Wajd · 2019

Among 5,452 new prescribed cannabinoid users, 18.1% continued use at 1 year.

Qualitative Analysis of Cannabis Use Among Older Adults in Colorado.

Bobitt, Julie · 2019

Five themes emerged from 17 focus groups: (1) older adults want more education and research about cannabis, (2) healthcare providers are not communicating about cannabis, (3) accessing medical cannabis is difficult, (4) medical cannabis users report positive outcomes, and (5) stigma continues to prevent open discussion.

A Survey of Cannabis Acute Effects and Withdrawal Symptoms: Differential Responses Across User Types and Age.

Sexton, Michelle · 2019

Most common acute effects: improved sleep, calmness, desire to eat, creativity, dry mouth.

The effects of marijuana smoking on lung function in older people.

Tan, Wan C · 2019

Among heavy marijuana users, the risk of COPD was significantly increased (adjusted OR 2.45, 95% CI 1.55-3.88).

Demographic trends among older cannabis users in the United States, 2006-13.

Han, Benjamin H · 2017

Analyzing data from 47,140 adults aged 50 and older in the National Survey on Drug Use and Health (2006-2013), researchers found significant increases in past-year cannabis use.

The Increasing Use of Cannabis Among Older Americans: A Public Health Crisis or Viable Policy Alternative?

Kaskie, Brian · 2017

This essay examined the intersection of cannabis and aging in America, identifying multiple pathways through which older adults are increasingly using cannabis. Some older adults are responding to changing social and legal environments and using cannabis recreationally.

Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Rahman, Haider · 2017

Nearly half of patients with inflammatory bowel disease (IBD) have used complementary and alternative medicine at some point, and elderly IBD patients face particular risks because they often take multiple medications for comorbid conditions. The review covers over 20 herbs commonly used by IBD patients, including cannabis, and details their potential interactions with standard IBD drugs like immunomodulators, biologics, and corticosteroids.

Relationship between marijuana and other illicit drug use and depression/suicidal thoughts among late middle-aged and older adults.

Choi, Namkee G · 2016

Researchers analyzed data from nearly 30,000 Americans aged 50 and older to examine the relationship between marijuana use and depression and suicidal thoughts in this understudied population. About 6% of adults over 50 reported past-year illicit drug use.

Pain, Depression, and Functional Outcomes Among Older Adults Who Use Cannabis or Opioid Analgesics for Chronic Pain Conditions.

Aebischer, Jonathan H · 2026

This longitudinal study tracked older adults enrolled in the Oregon Center for Aging and Technology with chronic pain lasting at least 12 weeks.

State Initiatives to Promote Cannabis Industry Entrepreneurship Among Disproportionately Impacted Communities: A Multi-State Analysis.

Chakraborty, Rishika · 2026

This multi-state analysis examined social equity entrepreneurship initiatives across all 17 states with legal non-medical cannabis retail as of May 2025.

Cannabis Use in Older Individuals May Be an Important and Under-Recognized Risk Factor for Motor Vehicle Crashes.

Pearlson, Godfrey D · 2026

This paper synthesized evidence on a collision of trends: the growing population of adults over 65 who drive, increasing cannabis use among older adults for medical and recreational purposes, and age-related factors that may amplify cannabis impairment. Older drivers already have more crashes per mile driven and are more likely to be injured or killed in crashes of similar magnitude.

Therapeutic use of cannabinoids in age-related pain: Current evidence and clinical perspectives.

Pulone, Sabina · 2026

This review explored the intersection of aging, chronic pain, and the endocannabinoid system (ECS), building a case for why cannabinoids might be particularly relevant for older adults. The key biological insight is that aging involves a process called "inflammaging" — chronic low-grade inflammation driven by immune system changes (immunosenescence).

Population pharmacokinetic modelling revealed large variability in oromucosal absorption of Δ9-tetrahydrocannabinol in older patients with poor appetite.

Storgaard, Ida Klitzing · 2026

THC pharmacokinetics in older patients showed enormous variability, with coefficient of variation ranging from 40.2% to 152% across pharmacokinetic parameters.

Agitation in Alzheimer's Disease as a Qualifying Condition for Medical Cannabis in the United States: A Brief Report on Current Trends.

Bonar, Erin E · 2025

Agitation in Alzheimer's disease is a devastating symptom affecting up to 70% of patients, and current pharmaceutical options carry significant risks, including increased mortality from antipsychotics.

The effects of naturalistic cannabis use on cognition and subjective experience in older adults with normal cognitive function.

Di Ciano, P · 2025

Trail making test performance (versions A and B) was significantly decreased 60 minutes after smoking cannabis compared to the sober condition.

Cannabidiol Modulates Brain Copper Homeostasis in Wild-Type-Like But Not Alzheimer's Disease Transgenic Female Mice: Implications for Neuroprotective Therapy.

Dosseto, Anthony · 2025

CBD elevated whole-brain copper in wild-type mice but not APP/PS1 transgenic mice.

In vivo and In vitro Crosstalk Among CBD, Aβ, and endocannabinoid system enzymes and receptors.

Duan, Fangyuan · 2025

CBD induced autophagy and apoptosis specifically in amyloid-beta-expressing cells via LC3B and Caspase-3 pathways, while producing side effects in non-pathological cells.

Effects of cannabidiol (CBD) treatment on age-related cognitive decline in C57 mice.

Mirza Agha, Behroo · 2025

Fourteen-month-old mice given oral CBD for 7 months showed reduced inflammatory response in the brain and improvements in age-related cognitive decline when tested between 19-21 months of age across tasks measuring perirhinal cortex, hippocampal, amygdala, and motor function..

The synthetic cannabinoid WIN 55,212-2 attenuates cognitive and motor deficits and reduces amyloid load in 5XFAD Alzheimer mice.

Möller, Johanna E L · 2025

Aged 5XFAD Alzheimer's mice treated with WIN 55,212-2 for 42 days showed improved rotarod motor performance, rescued water maze memory deficits, and reduced amyloid plaque burden and astrogliosis in the cortex and hippocampus compared to vehicle-treated controls..

Cannabinoid agonist WIN55,212-2 prevents scopolamine-induced impairment of spatial memory in rats.

Moreno-Rodríguez, Marta · 2025

Subchronic low-dose WIN55,212-2 (0.5 mg/kg) prevented scopolamine-induced spatial memory impairment in Barnes maze testing.

Cannabis use and cognition in older adults: Preliminary performance-based neuropsychological test results and directions for future research.

Mulhauser, Kyler · 2025

As cannabis use increases among older adults, a pressing question is whether it affects cognitive function in people already at risk for or experiencing cognitive decline.

The impact of cannabis use on ageing and longevity: a systematic review of research insights.

Nain, Sonam · 2025

Eleven preclinical studies showed promising results for cannabinoids in aging, including improved lifespan, cognitive function, reduced inflammation, better sleep, and enhanced social interaction.

The appetite stimulating effect and safety of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in older patients with poor appetite: A triple-blinded, randomized, placebo-controlled, cross-over trial.

Nielsen, Rikke Lundsgaard · 2025

No statistically significant difference in mean caloric intake was observed between cannabis-based medicine and placebo (10 kcal difference, CI -55 to 75 kcal, favoring CBM).

Chronic exposure to a synthetic cannabinoid improves cognition and increases locomotor activity in Tg4-42 Alzheimer's disease mice.

Ott, Frederik W · 2025

Therapeutic WIN 55,212-2 treatment rescued recognition memory and spatial reference deficits.

Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [18F]FMPEP-d 2 and [18F]MAGL-2102.

Pees, Anna · 2025

PET imaging revealed dynamic changes in cannabinoid receptor 1 (CB1) and MAGL enzyme availability across Alzheimer's disease progression.

Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial.

Pessoa, Rebeca Mendes P · 2025

CBD (300 mg/day for 4 weeks) significantly reduced scores on both the Neuropsychiatric Inventory (NPI, p=0.05) and the Brief Psychiatric Rating Scale (BPRS, p<0.05) compared to placebo.

A chronic low dose of Δ9-tetrahydrocannabinol (3 mg / kg / 21 d) reorganizes the disturbed wound healing process and accelerates wound closure in old female mice.

Plum, Melissa · 2025

Old female mice receiving daily low-dose THC (3 mg/kg) for three weeks before skin wounding showed improved wound healing rates between days 1 and 7.

Perceptions of cannabis among adults aged 60 years and older in Canada: a qualitative study.

Renard, Justine · 2025

Five themes emerged from 10 focus groups with 72 participants: common practices (primarily edibles and inhalation), general knowledge gaps, perceived harms (physical and cognitive effects, drug interactions), perceived benefits (pain management, mental health), and decreased stigma following legalization.

Development and Implementation of a Medical Cannabis Clinic Within a Geriatrics Primary Care Clinic: Preliminary Data.

Weaver, Ryan · 2025

Cannabis use among older adults is rising, but most use it without medical supervision—a gap this clinic aimed to fill.

Cumulative Deleterious Effects of Tetrahydrocannabinoid (THC) and Ethanol on Mitochondrial Respiration and Reactive Oxygen Species Production Are Enhanced in Old Isolated Cardiac Mitochondria.

Charles, Anne-Laure · 2024

THC impaired cardiac mitochondrial respiration in both young and old rats, but the effect was significantly worse in aged hearts (97.5% vs.

Characteristics of Cannabis and Opioid Users Among Older U.S. Veterans and Their Health Outcomes: A Longitudinal Perspective.

Kang, Hyojung · 2024

Older veterans reported positive outcomes for pain, sleep, and emotional problems across two survey periods.

Cannabidiol and Alzheimer's disease.

Marques, Bruno L · 2024

Preclinical studies show CBD can mitigate cognitive decline and amyloid-beta-induced neurodegeneration through modulation of oxidative stress and neuroinflammation.

Medicinal cannabis extracts are neuroprotective against Aβ1-42-mediated toxicity in vitro.

Marsh, Dylan T · 2024

Five proprietary cannabis extracts were tested against amyloid-beta toxicity in PC12 cells.

Exploring Cannabinoids with Enhanced Binding Affinity for Targeting the Expanded Endocannabinoid System: A Promising Therapeutic Strategy for Alzheimer's Disease Treatment.

Stanciu, Gabriela Dumitrita · 2024

Chronic treatment with JWH-133 (a selective CB2 agonist) and Cannabis sativa extract reduced anxiety-like behavior and partially reversed recognition memory deficits in APP/PS1 mice.

Prevention, Practice, and Policy: Older US Veterans' Perspectives on Cannabis Use.

Bobitt, Julie · 2023

Semi-structured interviews with 32 older veterans revealed they used medical cannabis as an adjunct or substitute for opioids and benzodiazepines for physical and mental health conditions.

Assessing Cannabidiol as a Therapeutic Agent for Preventing and Alleviating Alzheimer's Disease Neurodegeneration.

Chen, Long · 2023

CBD demonstrated protective effects against amyloid-beta toxicity both in cell cultures and in mice, ameliorating cognitive impairment.

Assessing Efficacy and Use Patterns of Medical Cannabis for Symptom Management in Elderly Cancer Patients.

Nathan, Rachel · 2023

There was no statistically significant difference in symptom scores for pain, nausea, appetite, insomnia, or anxiety before versus after medical cannabis initiation.

The different role of G-protein-coupled receptor 30 (GPR30) in the interaction effects of marijuana and estradiol on spatial learning and memory at different ages.

Chahkandi, Mohadeseh · 2022

Marijuana alone improved spatial learning in both young and old female rats.

Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer's disease.

Coles, Madilyn · 2022

CBD reversed and prevented cognitive deficits in AD rodent models through anti-inflammatory, antioxidant, and neuroprotective mechanisms.

Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.

Costa, Alana C · 2022

This review confronted a growing clinical reality: older adults with Parkinson's disease and dementia are increasingly using cannabinoids, but the evidence supporting this use is almost entirely preclinical.

Cannabis and End-of-Life Care: A Snapshot of Hospice Planning and Experiences Among Illinois Medical Cannabis Patients With A Terminal Diagnosis.

Croker, James Alton · 2022

Only 19 of 342 terminal patients were enrolled in hospice, with 323 planning enrollment.

Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients.

Pautex, Sophie · 2022

Managing behavioral symptoms in severe dementia — agitation, aggression, wandering, sleep disruption — is one of the hardest challenges in elder care.

Cannabidiol-Treated Ovariectomized Mice Show Improved Glucose, Energy, and Bone Metabolism With a Bloom in Lactobacillus.

Sui, Ke · 2022

CBD-treated ovariectomized mice had improved oral glucose tolerance, increased energy expenditure, and improved bone mineral density and bone microarchitecture.

Cannabis and its therapeutic value in the ageing population: Attitudes of health-care providers.

Chandiok, Karan · 2021

Providers were generally positive about medical cannabis for older patients but identified multiple barriers: stigma from patients and colleagues, complex regulatory pathways (Special Access Scheme), limited access in rural areas, restrictive driving laws, and insufficient education and evidence..

Effectiveness of Cannabinoids for Treatment of Dementia: A Systematic Review of Randomized Controlled Trials.

Charernboon, Thammanard · 2021

Nabilone (1-2 mg/day) showed significant improvement in agitation in one trial.

Increased Likelihood of Falling in Older Cannabis Users vs. Non-Users.

Workman, Craig D · 2021

Cannabis-using older adults showed higher fall risk scores, poorer one-leg standing balance, and slower gait speed compared to matched non-users.

Age-dependent hormesis-like effects of the synthetic cannabinoid CP55940 in C57BL/6 mice.

Hodges, Erik L · 2020

CP55940 produced greater antinociception (pain relief) and locomotor inhibition in aged (21-24 month) compared to young-adult (4 month) mice.

Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer's Disease.

Schubert, David · 2019

Nine of 11 cannabinoids protected cells in four distinct neurodegeneration assays (proteotoxicity, trophic loss, oxidative stress, energy loss).

Increased Use of Medical Marijuana: Skepticism vs. Evidence.

Wick, Jeannette Y · 2018

Medical marijuana use is growing among long-term care residents.

Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients.

Haug, Nancy A · 2017

This dispensary-based study compared 217 medical cannabis patients across three age groups: younger (18-30), middle-aged (31-50), and older (51-72). All age groups used cannabis at similar frequencies over the past month.

Drug use among HIV+ adults aged 50 and older: findings from the GOLD II study.

Ompad, Danielle C · 2016

In a sample of 95 HIV-positive patients aged 50 and older who were actively engaged in medical care, substance use was highly prevalent.

Accidental cannabis poisoning in the elderly.

Zupan Mežnar, Anja · 2016

During a workshop on hemp's medicinal uses, attendees sampled various hemp food products.

The California program for the investigational use of THC and marihuana in heterogeneous populations experiencing nausea and vomiting from anticancer therapy.

Dow, G J · 1981

Recognizing that existing THC studies left major questions unanswered, California established a statewide program combining therapeutic access with structured research. Four protocols were designed to address specific gaps: optimal oral THC dosing in adults on cyclic chemotherapy, optimal dosing in children, dosing for adults on chronic chemotherapy or radiation therapy, and optimal dosing for smoked marijuana.

Older Adults' Use of Cannabis and Attitudes Around Disclosing Medical Cannabis Use to Their Healthcare Providers in California: A Mixed Methods Study.

Abu Baker, Dania · 2024

Older adults frequently did not disclose medical cannabis use to their primary care providers.

Association Between Cannabis Use and Subjective Cognitive Decline: Findings from the Behavioral Risk Factor Surveillance System (BRFSS).

Chen, Zhi · 2024

Non-medical cannabis use was associated with 96% decreased odds of subjective cognitive decline (aOR=0.04, 95% CI: 0.01-0.44, p<.01).

Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.

Wolfe, Dianna · 2023

Cannabis use is increasing among older adults following legalization.